By Alex McGuire, Associate Editor, Money Morning • @AlexMcGuire92 - • Print | Email
The VRX stock price saw one of its worst single-day performances of the year yesterday.
Shares plunged after CEO J. Michael Pearson took a medical leave of absence due to pneumonia.
Now investors are wondering if the stock is bottoming out and ready to move higher in 2016...
By Money Morning Staff Reports, Money Morning - • Print | Email
Our "most hated companies 2015" list includes five companies that stole, poisoned, and defrauded their way to profits this year – and did so unapologetically.
Have a look at what these loathsome companies accomplished in 12 short months...
By Diane Alter, Contributing Writer, Money Morning - • Print | Email
The Valeant Pharmaceutical International Inc. (NYSE: VRX) stock price has come under pressure yet again this week following a new downgrade and significantly lowered company guidance.
Late last week, Valeant lowered its Q4 outlook and guided Q1 fiscal 2016 sales and earnings below Wall Street estimates.
Here's why we see the VRX stock price drop continuing into 2016...
By David Zeiler, Associate Editor, Money Morning • @DavidGZeiler - • Print | Email
When hedge fund manager Bill Ackman warned his shareholders Tuesday that 2015 would likely be his worst ever, most investors probably had the same reaction: "I'm glad I don't have any money with that guy."
But celebrity investors like Bill Ackman – who has built a reputation as one of the top activist investors – have big followings among retail investors.
By Diane Alter, Contributing Writer, Money Morning - • Print | Email
The Valeant Pharmaceuticals Inc. (NYSE: VRX) stock price soared some 16% to $110.98 Tuesday, but we remain bearish on the embattled drug maker in 2016.
You see, the company still faces a number of high hurdles.
Here's what you need to know...
By Money Morning Staff Reports, Money Morning - • Print | Email
Four of the most outrageous drug price increases in 2015 were born purely of greed…
Most of us have heard about Turing Pharmaceutical's CEO Martin Shkreli's infamous price-gouging incident.
But check out our chart to see four drug price hikes that were even more massive this year...
By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - • Print | Email
There's been a ton of online chatter claiming that Valeant stock has become a screaming bargain.
And sure, it sounds like a bottom-feeder's dream come true. Since its Aug. 5 high, Valeant stock has dropped more than 65%. If it regained just 69% of its previous high, it would double.
But don't believe the hype. This is a deeply troubled company you should stay well away from.
Let me show you why you'll be glad you avoided this company at all costs...
By Diane Alter, Contributing Writer, Money Morning - • Print | Email
The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price has dropped 44% year to date and nearly 80% over the last three months.
While some are saying VRX stock has now become undervalued, Money Morning Global Credit Strategist Michael Lewitt says the Valeant stock price will only continue to fall.
By Diane Alter, Contributing Writer, Money Morning - • Print | Email
The Valeant stock drop has now reached nearly 46% this week. Today (Thursday), Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock is down another 20% as shares trade near $95.
The worst Valeant stock drop happened Wednesday when shares fell 40% intraday amid a scathing report from Citron Research. VRX stock ended Wednesday's session down 19%.
Here's what caused the sell-off and why Valeant shares may have further to fall...
